Net Asset Value calculation to 31 March 2016

RNS Number : 7471W

Port Erin Biopharma Investments Ltd

28 April 2016

 

29 April 2016

Port Erin Biopharma Investments Limited

(the "Company")

Net Asset Value calculation to 31 March 2016

Jim Mellon, Chairman, commented: -

"The Net Asset Value ("NAV") calculation for the Company as at closing on 31 March 2016 was 10.21 pence per share, including un-invested cash of £10,713. The portfolio is valued under IFRS at bid price.

Net Assets stand at £2.4 million including Investments of £2.38 million. This quarter's NAV represents a decrease of 5.37% from the previous valuation of 10.79 pence per share, which included un-invested cash of £24,011. No additional management fee is due to Shellbay Investments Limited."

		Unaudited to 31 March 2016 (£)
Fixed Assets
	Investments	2,375,370
Current Assets
	Sundry Debtors	34,522
	Uninvested cash	10,713
Current Liabilities
	Creditors: amounts due	(51,777)
		2,368,828
Capital and Reserves
	Share Capital	23
	Share Premium	1,890,142
	Reserves	478,663
		2,368,828
Shares in Issue		23,195,558
Net Asset Value per share		10.21 pence

Portfolio Details

Investments as at 31 March 2016	Value	% of Total Portfolio
Magna Biopharma Income Fund	£1,093,235	46.0%
Regent Pacific Group	£600,945	25.3%
Summit Corporation	£251,293	10.6%
Other quoted holdings	£96,082	4.0%
Other unquoted holdings	£333,815	14.1%
Total	£2,375,370	100.0%

For further information, please contact:

Port Erin Biopharma Investments Limited	Northland Capital Partners Limited	Peterhouse Capital Limited
The Company	Nomad and Joint Broker	Broker
Denham Eke (+44) (0) 1624 639396	Matthew Johnson/David Hignell (+44) (0) 203 861 6625	Lucy Williams (+44) (0) 207 469 0936

 

END

 

 

NAVSELESAFMSESL